Tempus AI, Inc., a Chicago-based leader in AI-driven precision medicine, announced on July 1, 2025, the pricing of a $650 million offering of 0.75% Convertible Senior Notes due 2030, upsized from an initial $400 million. The private placement, targeting qualified institutional buyers under Rule 144A, is set to close on July 3, 2025, subject to customary conditions.
Offering Details: $650M in 0.75% Convertible Senior Notes due July 15, 2030, with a $100M over-allotment option.
Net Proceeds: ~$625.3M, or $721.7M if over-allotment is fully exercised, after fees and $36.2M for capped call transactions.
Use of Proceeds: Repay $274.7M in senior secured term loans, fund capped calls, and support general corporate purposes (e.g., acquisitions, working capital).
Conversion Terms: Initial conversion price of $84.19 (32.5% premium over June 30, 2025, closing price); convertible after April 15, 2030, or earlier under specific conditions.
Stock Performance: TEM at $62.358 (per finance card above), down 1.8% after insider selling and 2.6% post-announcement.
Market Context: Q1 2025 genomics revenue up 89% to $193.8M; stock up 90% YTD.
The $650M offering, with a low 0.75% coupon, aims to optimize Tempus’ capital structure by retiring $274.7M in high-cost senior secured term loans, reducing interest expenses. The remaining proceeds will fund capped call transactions to mitigate dilution and support strategic initiatives, including acquisitions and AI platform enhancements. “This strategic move enhances financial flexibility,” noted analysts, aligning with Tempus’ growth in the $30B precision medicine market.
The notes, unsecured and maturing on July 15, 2030, offer a conversion price of $84.19, a 32.5% premium over the June 30, 2025, closing price of $63.54 (per finance card above). Capped call transactions, with a cap price of $111.195 (75% premium), further reduce dilution risks.
As shown in the finance card above, TEM’s stock price is $62.358, down 1.8% following CEO Eric Lefkofsky’s sale of 250,000 shares at $70.07 on June 17, 2025, and 2.6% after the offering announcement. Despite short-term volatility, the stock has gained 90% YTD from $33.76 in December 2024, driven by an 89% Q1 2025 genomics revenue surge to $193.8M, fueled by oncology testing and the Ambry Genetics acquisition.
Posts on X reflect mixed sentiment, with @FilingsTracker and @AIStockSavvy noting the offering’s potential to reduce debt but highlighting a 2.9% pre-market drop. A shareholder lawsuit alleging misleading statements about related-party deals and the Ambry acquisition adds risk, though analysts remain bullish, citing partnerships with Verastem Oncology and a $15.2B market cap.
Tempus’ focus on AI-driven precision medicine, including its FDA-approved xT CDx assay and collaborations with Northwestern University and Verastem, positions it in a $30B market growing at 14% annually. The offering’s proceeds will bolster initiatives like the Verastem Phase 3 RAMP-301 trial, enhancing Tempus’ role in oncology. However, a debt-to-equity ratio of 2.45 and ongoing litigation pose challenges.
Tempus’ $650M convertible notes offering strengthens its financial foundation, enabling debt reduction and investment in AI-driven healthcare solutions, solidifying its leadership in precision medicine.
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data.
TechIntelPro empowers B2B technology decision-makers with the latest industry trends, deep insights, leadership perspectives and actionable intelligence to drive both organizational and professional milestones—and thrive on the tech pulse.